Aquestive (AQST) benefits from Trump-era tariffs, with FDA approval driving positive outlook and analysts reaffirming Buy ratings.
1 report, 0 independent
Updated Jul 3
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Aquestive (AQST) benefits from Trump-era tariffs, with FDA approval driving positive outlook and analysts reaffirming Buy ratings.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Aquestive (United States)
company in Warren Township, United States
Nothing else this week.
- FDA
-
Donald Trump
American businessman and politician (born 1946), President of the United States (2017–2021; since 2025)
Related events
- Goldman Sachs and Zeta Interactive noted that tariffs and onshoring benefit AI stocks, citing accelerated Q2 growth and raising price targets.
- Barclays raised its price target for Okta, noting that AI stocks are benefiting from the onshoring trend and Trump-era tariffs.
- AI stocks are benefiting from Trump-era tariffs, with Morningstar and ClearBridge providing market analysis on growth and upside potential.
- AI stocks are benefiting from Trump-era tariffs, and Brian Schwartz maintained an Outperform rating on Workday on September 5th.
- SharpLink Gaming acquired Ethereum above market prices, causing a stock price drop, while Trump tariffs continue to benefit AI stocks.
Coverage
Newest first; wire copies grouped- Unknown outlet